葛兰素史克（GSK）

个人简介:从事药物代谢和生物分析工作18年，特别是负责开发以液相-质谱为平台的，符合严苛药物监管标准的药物，代谢物及生物标志物的定量分析方法。研究兴趣包括：小分子药物代谢机理，抗体药物偶联物, 蛋白降解靶向嵌合体，寡核苷酸及代谢物的定量， 药物前体分析，核苷类药物在血周细胞内代谢物的定量分析，以病患为中心的微取样技术等。曾获GSK“变革性药物与疫苗奖”（2024）、GSK “生物学日”受邀报告人（2026）及海报奖（2025）, “最具影响力研发人员奖”（2023）, 20余项研发奖（3金奖 10银）等。发表同行评议期刊论文8篇，在包括美国化学会（ACS），美国质谱学会（ASMS），美国药企/药监局生物分析研讨会（WRIB) 等重要会议上作口头报告10 次以上。 A bioanalytical and DMPK expert with 18 years of pharmaceutical experience spanning from discovery-phase ADME investigation through late-phase regulated bioanalysis. A seasoned method developer, with deep expertise in developing advanced LC-MS methodologies to meet rigorous regulatory requirements in support of clinical and non-clinical PK studies. Proven ability to lead complex projects (e.g., ADCs, PROTACs, Oligonucleotides, intracellular PK, prodrugs, patient centric microsampling, etc.) throughout development phases.Recognition includes GSK’s prestigious Transformational Medicines and Vaccines Award (2024), an invitation as a GSK Biology Day Invited Speaker (2026), a GSK Biology Day Poster Winner (2025), and the Most Impactful R&D Performer Award (2023), in addition to 20+ R&D recognition awards (3 Gold, 10 Silver). Has published 8 papers in peer-reviewed journals and delivered 10+ oral presentations at international meetings (WRIB, ASMS, ACS, etc.). 查看更多